Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

The current state of health services highlights crucial sectors facing disruptions and developments, from US foreign aid freezes affecting disease control supply chains, to the FDA's actions on new ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion ...

Novo Nordisk's stock closed about 5% higher on ... weight loss drugs such as Wegovy are not currently covered by Medicare and other insurance. Don't expect a 20% S&P 500 three-peat this year ...

The Centers for Medicare & Medicaid Services reported ... beating its benchmark by 150 percentage points (see more details here). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company ...